Merlin Nexus and New Leaf Venture Partners, stockholders in Icagen, Inc. ICGN, disclosed today a letter submitted to the Icagen Board contesting the Company's planned acquisition by Pfizer Inc PFE.
According to a July 20, 2011 press announcement, Pfizer plans to purchase the 8.3 million shares of Icagen stock it already does not own at a price of $6.00 per share, resulting in an aggregate transaction value of approximately $56 million. Merlin Nexus and NLV Partners “believe the purchase price dramatically undervalues Icagen's assets and is not in the best interests of all stockholders.”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in